- UroToday Home
- Trials in Progress
Trials in Progress
PROMISE PCCTC Study: Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Trials in Progress
Videos
Publications
Articles and Abstracts
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium - Beyond the Abstract
Germline testing for prostate cancer (PCA) is revolutionizing treatment, management, and risk assessment. Pathogenic mutations in multiple DNA repair genes, and particularly BRCA2 and others, are informing targeted therapy options in the metastatic and advanced disease setting, active surveillance discussions in the early-stage setting, and PCA early detection discussions.1
Read More
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Germline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for precision therapies. The Prostate Cancer Clinical Trials Consortium (PCCTC) established the Germline Genetics Working Group to provide guidance and resources to expand effective use of germline genetic testing.
Read More
Conference Coverage
Conference Highlights Written by Physician-Scientist
ASCO GU 2022: Implications of Androgen Receptor (AR) Alterations Identified by Genomic Testing of Tissue and Blood from Advanced Prostate Cancer (aPC) Patients
Presented by Zeynep Busra Zengin, MD
Novel androgen receptor targeted agents (ARTA) are effective in improving patient outcomes across the spectrum of prostate cancer disease states. Resistance to ARTAs eventually develops in advanced prostate cancer, and a broader understanding of the mechanisms promoting this resistance is required. Read More
ASCO GU 2022: PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Presented by Channing Judith Paller, MD
A substantial minority of patients with prostate cancer have germline mutations in genes involved in DNA damage repair. Based on the prevalence of these alterations in advanced disease and the potential therapeutic benefit of targeting germline DNA damage repair vulnerabilities, treatment guidelines recommend genetic testing in high-risk localized, node positive, and metastatic disease. Read More